Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.

MLA

Tam, Constantine S., et al. “Zanubrutinib versus Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (SEQUOIA): A Randomised, Controlled, Phase 3 Trial.” The Lancet. Oncology, vol. 23, no. 8, Aug. 2022, pp. 1031–43. EBSCOhost, https://doi.org/10.1016/S1470-2045(22)00293-5.

APA

Tam, C. S., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Jurczak, W., Šimkovič, M., Shadman, M., Österborg, A., Laurenti, L., Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trněný, M., Brander, D. M., Flinn, I. W., … Hillmen, P. (2022). Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. The Lancet. Oncology, 23(8), 1031–1043. https://doi.org/10.1016/S1470-2045(22)00293-5

Chicago

Tam, Constantine S, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, et al. 2022. “Zanubrutinib versus Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (SEQUOIA): A Randomised, Controlled, Phase 3 Trial.” The Lancet. Oncology 23 (8): 1031–43. doi:10.1016/S1470-2045(22)00293-5.